Dr. Daniel G. Billen
Equibles does not estimate personal net worth.
About Dr. Daniel G. Billen
Aurinia Pharmaceuticals Inc. reported in an 8-K filed September 12, 2024 that Dr. Daniel G. Billen resigned as Director. Aurinia Pharmaceuticals Inc. reported in an 8-K filed September 12, 2024 that Dr. Daniel G. Billen resigned as director, effective September 9, 2024.
“The Board has accepted the conditional resignations of Daniel G. Billen, Ph.D., R. Hector MacKay-Dunn, J.D., and Brinda Balakrishnan, M.D., Ph.D., who received less than majority support at the Meeting.”
“the Board, following the deliberation process outlined in the Company's Majority Voting Policy, determined (i) to accept the resignations of Dr. Billen, Mr. MacKay-Dunn, and Dr. Balakrishnan, effective September 9, 2024”
Affiliation history
-
Aurinia Pharmaceuticals Inc. (AUPH)
Proxy statement
Start not stated–2024-05-03
Last confirmed by a filing; no departure on record